General Information of the Protein
Protein ID
PT06087
Protein Name
ATP-binding cassette sub-family C member 9
Secondarily
Protein Name
Sulfonylurea receptor 2
Gene Name
ABCC9
Secondarily
Gene Name
SUR2
Sequence
MSLSFCGNNISSYNINDGVLQNSCFVDALNLVPHVFLLFITFPILFIGWGSQSSKVQIHHNTWLHFPGHNLRWILTFALLFVHVCEIAEGIVSDSRRESRHLHLFMPAVMGFVATTTSIVYYHNIETSNFPKLLLALFLYWVMAFITKTIKLVKYCQSGLDISNLRFCITGMMVILNGLLMAVEINVIRVRRYVFFMNPQKVKPPEDLQDLGVRFLQPFVNLLSKATYWWMNTLIISAHKKPIDLKAIGKLPIAMRAVTNYVCLKDAYEEQKKKVADHPNRTPSIWLAMYRAFGRPILLSSTFRYLADLLGFAGPLCISGIVQRVNETQNGTNNTTGISETLSSKEFLENAYVLAVLLFLALILQRTFLQASYYVTIETGINLRGALLAMIYNKILRLSTSNLSMGEMTLGQINNLVAIETNQLMWFLFLCPNLWAMPVQIIMGVILLYNLLGSSALVGAAVIVLLAPIQYFIATKLAEAQKSTLDYSTERLKKTNEILKGIKLLKLYAWEHIFCKSVEETRMKELSSLKTFALYTSLSIFMNAAIPIAAVLATFVTHAYASGNNLKPAEAFASLSLFHILVTPLFLLSTVVRFAVKAIISVQKLNEFLLSDEIGDDSWRTGESSLPFESCKKHTGVQPKTINRKQPGRYHLDSYEQSTRRLRPAETEDIAIKVTNGYFSWGSGLATLSNIDIRIPTGQLTMIVGQVGCGKSSLLLAILGEMQTLEGKVHWSNVNESEPSFEATRSRNRYSVAYAAQKPWLLNATVEENITFGSPFNKQRYKAVTDACSLQPDIDLLPFGDQTEIGERGINLSGGQRQRICVARALYQNTNIVFLDDPFSALDIHLSDHLMQEGILKFLQDDKRTLVLVTHKLQYLTHADWIIAMKDGSVLREGTLKDIQTKDVELYEHWKTLMNRQDQELEKDMEADQTTLERKTLRRAMYSREAKAQMEDEDEEEEEEEDEDDNMSTVMRLRTKMPWKTCWRYLTSGGFFLLILMIFSKLLKHSVIVAIDYWLATWTSEYSINNTGKADQTYYVAGFSILCGAGIFLCLVTSLTVEWMGLTAAKNLHHNLLNKIILGPIRFFDTTPLGLILNRFSADTNIIDQHIPPTLESLTRSTLLCLSAIGMISYATPVFLVALLPLGVAFYFIQKYFRVASKDLQELDDSTQLPLLCHFSETAEGLTTIRAFRHETRFKQRMLELTDTNNIAYLFLSAANRWLEVRTDYLGACIVLTASIASISGSSNSGLVGLGLLYALTITNYLNWVVRNLADLEVQMGAVKKVNSFLTMESENYEGTMDPSQVPEHWPQEGEIKIHDLCVRYENNLKPVLKHVKAYIKPGQKVGICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQDPILFSGSIRFNLDPECKCTDDRLWEALEIAQLKNMVKSLPGGLDAVVTEGGENFSVGQRQLFCLARAFVRKSSILIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVSSIMDAGLVLVFSEGILVECDTVPNLLAHKNGLFSTLVMTNK
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Transporter
>
Primary active transporter
>
ATP-binding cassette
>
ABCC subfamily
Function
Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.
    Show/Hide
Uniprot ID
Primary ID:
O60706

Secondarily ID:
O60707
    Show/Hide
Ensembl ID
ENSG00000069431
HGNC ID
HGNC:60
Subcellular Location
Membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000005 , TE 671
Compound ID Compound Name Compound Formula
CP0434933
(-)-3-chlorophenyl (3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-ylcarbamate
   Show/Hide
C19H17ClN2O3
 1
1
EC50 = 70 nM
   TI
   LI
   LO
   TS
CP0434938
(+/-)-3-chlorophenyl 6-cyano-3-hydroxy-2,2-dimethylchroman-4-ylcarbamate
   Show/Hide
C19H17ClN2O3
 1
1
EC50 = 120 nM
   TI
   LI
   LO
   TS
CP0009138
CAS_60559-98-0
   Show/Hide
C12H17N5
 1
1
EC50 = 230 nM
   TI
   LI
   LO
   TS
CP0462312
(+/-)-3-chlorophenyl 6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl carbonate
   Show/Hide
C19H16ClNO4
 1
1
EC50 = 310 nM
   TI
   LI
   LO
   TS
CP0422815
4-chloro-N-((3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)nicotinamide
   Show/Hide
C18H16ClN3O3
 1
1
EC50 = 560 nM
   TI
   LI
   LO
   TS
CP0422795
(3S,4R)-4-(6-chloro-3-oxo-3H-benzo[d]isoxazol-2-yl)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H15ClN2O4
 1
1
EC50 = 670 nM
   TI
   LI
   LO
   TS
CP0523014
(3S,4R)-2-(6-Benzenesulfonyl-3-hydroxy-2,2-dimethylchroman-4-yl)-6-chloro-benzo[d]isoxazol-3-one
   Show/Hide
C24H20ClNO6S
 1
1
EC50 = 750 nM
   TI
   LI
   LO
   TS
CP0374095
(+/-)-4-chlorophenyl 6-cyano-3-hydroxy-2,2-dimethylchroman-4-ylcarbamate
   Show/Hide
C19H17ClN2O3
 1
1
EC50 = 780 nM
   TI
   LI
   LO
   TS
CP0526204
N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-1,3-benzodioxole-5-carboxamide
   Show/Hide
C20H18N2O5
 1
1
EC50 = 810 nM
   TI
   LI
   LO
   TS
CP0467669
(3S,4R)-(5-Chloro-3-oxo-3H-benzo[d]isoxazol-2-yl)-3-hydroxy-2,2-dimethyl-chroman-6-sulfonic acid diethylamide
   Show/Hide
C22H25ClN2O6S
 1
1
EC50 = 820 nM
   TI
   LI
   LO
   TS
CP0463809
(3S,4R)-6-Chloro-2-[3-hydroxy-2,2-dimethyl-6-(piperidine-1-sulfonyl)-chroman-4-yl]-benzo[d] isoxazol-3-one
   Show/Hide
C23H25ClN2O6S
 1
1
EC50 = 1080 nM
   TI
   LI
   LO
   TS
CP0022488
CAS_94535-50-9
   Show/Hide
C16H18N2O3
 1
1
EC50 = 1250 nM
   TI
   LI
   LO
   TS
CP0422810
(3S,4R)-6-Benzenesulfonyl-4-(5-chloro-benzo[d]-isoxazol-3-ylamino)-chroman-3-ol
   Show/Hide
C24H21ClN2O5S
 1
1
EC50 = 1370 nM
   TI
   LI
   LO
   TS
CP0374104
(3S,4R)-4-[5-(4-Chloro-phenyl)-pyrazol-1-yl]-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C21H18ClN3O2
 1
1
EC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0374103
3-chloro-N-((3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)benzenesulfonamide
   Show/Hide
C18H17ClN2O4S
 1
1
EC50 = 1540 nM
   TI
   LI
   LO
   TS
CP0422804
(3S,4R)-2-(6-Benzenesulfonyl-3-hydroxy-2,2-dimethylchroman-4-yl)-5-chloro-4-benzo[d] isoxazol-3-one
   Show/Hide
C24H20ClNO6S
 1
1
EC50 = 1560 nM
   TI
   LI
   LO
   TS
CP0519219
(3S,4R)-4-[5-(4-Chloro-phenyl)-pyrazol-1-yl]-2,2-dimethyl-3,4-dihydro-2H-pyrano[3,2-c]pyridin-3-ol
   Show/Hide
C19H18ClN3O2
 1
1
EC50 = 1640 nM
   TI
   LI
   LO
   TS
CP0422800
(3S,4R)-6-Chloro-2-[6-(3-fluoro-benzenesulfonyl)-3-hydroxy-2,2-dimethyl-chroman-4-yl]-benzo[d]isoxazol-3-one
   Show/Hide
C24H19ClFNO6S
 1
1
EC50 = 1710 nM
   TI
   LI
   LO
   TS
CP0444597
(+)-3-chlorophenyl (3R,4S)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-ylcarbamate
   Show/Hide
C19H17ClN2O3
 1
1
EC50 = 2070 nM
   TI
   LI
   LO
   TS
CP0444596
(3S,4R)-4-(6-Chloro-4-oxo-1,4-dihydro-quinazolin-2-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C20H17ClN4O3
 1
1
EC50 = 2290 nM
   TI
   LI
   LO
   TS
CP0453661
(3S,4R)-4-(5-chloro-3-oxobenzo[d]isoxazol-2(3H)-yl)-3-hydroxy-2,2-dimethylchroman-6-carbonitrile
   Show/Hide
C19H15ClN2O4
 1
1
EC50 = 2440 nM
   TI
   LI
   LO
   TS
CP0463808
(3S,4R)-4-(5-Ethoxy-benzothiazol-2-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C21H21N3O3S
 1
1
EC50 = 2600 nM
   TI
   LI
   LO
   TS
CP0493444
(3S,4R)-4-[2-(4-Chloro-phenyl)-imidazol-1-yl]-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C21H18ClN3O2
 1
1
EC50 = 2750 nM
   TI
   LI
   LO
   TS
CP0374094
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(5-nitrobenzothiazol-2-ylamino)-chroman-6-carbonitrile
   Show/Hide
C19H16N4O4S
 1
1
EC50 = 3090 nM
   TI
   LI
   LO
   TS
CP0422802
(3S,4R)-4-(5-Chloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C20H15ClN2O4
 1
1
EC50 = 3160 nM
   TI
   LI
   LO
   TS
CP0021671
CAS_85371-64-8
   Show/Hide
C13H19N5
 1
1
EC50 = 3540 nM
   TI
   LI
   LO
   TS
CP0422811
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(4-oxo-1,4-dihydroquinazolin-2-ylamino)-chroman-6-carbonitrile
   Show/Hide
C20H18N4O3
 1
1
EC50 = 3710 nM
   TI
   LI
   LO
   TS
CP0481597
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(6-nitro-3-oxo-3Hbenzo[d]isothiazol-2-yl)-chroman-6-carbonitrile
   Show/Hide
C19H15N3O5S
 1
1
EC50 = 4100 nM
   TI
   LI
   LO
   TS
CP0434937
(3S,4R)-4-[2-(4-Chloro-phenyl)-imidazol-1-yl]-2,2-dimethyl-3,4-dihydro-2H-pyrano[3,2-c] pyridin-3-ol
   Show/Hide
C19H18ClN3O2
 1
1
EC50 = 4330 nM
   TI
   LI
   LO
   TS
CP0481596
(3S,4R)-4-(1,3-Dioxo-1,3-dihydro-pyrrolo[3,4-c]pyridin-2-yl)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H15N3O4
 1
1
EC50 = 6040 nM
   TI
   LI
   LO
   TS
CP0433784
(3S,4R)-4-(6-Chloro-benzo[d]isoxazol-3-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H16ClN3O3
 1
1
EC50 = 6180 nM
   TI
   LI
   LO
   TS
CP0422799
(3S,4R)-2-(6-Benzoyl-3-hydroxy-2,2-dimethyl-chroman-4-yl)-6-chloro-4-benzo[d]isoxazol-3-one
   Show/Hide
C25H20ClNO5
 1
1
EC50 = 6450 nM
   TI
   LI
   LO
   TS
CP0422793
(3S,4R)-4-(5-Chloro-1H-indazol-3-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H17ClN4O2
 1
1
EC50 = 6850 nM
   TI
   LI
   LO
   TS
CP0422805
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(3-oxo-3H-benzo[d]-isoxazol-2-yl)-chroman-6-carbonitrile
   Show/Hide
C19H16N2O4
 1
1
EC50 = 6940 nM
   TI
   LI
   LO
   TS
CP0434934
3,4-dichloro-N-((3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)benzamide
   Show/Hide
C19H16Cl2N2O3
 1
1
EC50 = 7060 nM
   TI
   LI
   LO
   TS
CP0422803
(3S,4R)-6-Chloro-[2-hydroxy-6-(4-methoxy-benzenesulfonyl)-2,2-dimethyl-chroman-4-yl]-benzo[d]isoxazol-3-one
   Show/Hide
C25H22ClNO7S
 1
1
EC50 = 7330 nM
   TI
   LI
   LO
   TS
CP0415592
(3S,4R)-4-[5-(4-Chloro-phenyl)-imidazol-1-yl]-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C21H18ClN3O2
 1
1
EC50 = 7450 nM
   TI
   LI
   LO
   TS
CP0422808
(3S,4R)-4-(5-Chloro-benzo[d]isoxazol-3-ylamino)-6-(3-fluoro-benzenesulfonyl)-2,2-dimethyl-chroman-3-ol
   Show/Hide
C24H20ClFN2O5S
 1
1
EC50 = 7770 nM
   TI
   LI
   LO
   TS
CP0433783
(3S,4R)-4-(6-Chloro-benzo[d]isoxazol-3-yloxy)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H15ClN2O4
 1
1
EC50 = 7850 nM
   TI
   LI
   LO
   TS
CP0515751
(3S,4R)-6-Chloro-2-[6-(4-chloro-benzenesulfonyl)-3-hydroxy-2,2-dimethyl-chroman-4-yl]-benzo[d]isoxazol-3-one
   Show/Hide
C24H19Cl2NO6S
 1
1
EC50 = 7990 nM
   TI
   LI
   LO
   TS
CP0462311
(3S,4R)-4-(5-Fluoro-benzothiazol-2-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H16FN3O2S
 1
1
EC50 = 8440 nM
   TI
   LI
   LO
   TS
CP0422797
(3S,4R)-6-Chloro-2-(6,7-dichloro-3-hydroxy-2,2-dimethyl-chroman-4-yl)-benzo[d]isoxazol-3-one
   Show/Hide
C18H14Cl3NO4
 1
1
EC50 = 10300 nM
   TI
   LI
   LO
   TS
CP0422812
(3S,4R)-2,2-Dimethyl-4-(2-phenyl-imidazol-1-yl)-3,4-dihydro-2H-pyrano[3,2-c]pyridin-3-ol
   Show/Hide
C19H19N3O2
 1
1
EC50 = 12900 nM
   TI
   LI
   LO
   TS
CP0453659
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-phenyl-imidazol-1-yl)-chroman-6-carbonitrile
   Show/Hide
C21H19N3O2
 1
1
EC50 = 13000 nM
   TI
   LI
   LO
   TS
CP0384666
(3S,4R) 4-[5-(4-Chloro-phenyl)-imidazol-1-yl]-2,2-dimethyl-3,4-dihydro-2H-pyrano[3,2-c]pyridin-3-ol
   Show/Hide
C19H18ClN3O2
 1
1
EC50 = 13800 nM
   TI
   LI
   LO
   TS
CP0433785
(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxobenzo[d]isothiazol-2(3H)-yl)chroman-6-carbonitrile
   Show/Hide
C19H16N2O3S
 1
1
EC50 = 14100 nM
   TI
   LI
   LO
   TS
CP0433782
(3S,4R)-4-(5-Chloro-1H-benzoimidazol-2-ylsulfanyl)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H16ClN3O2S
 1
1
EC50 = 14700 nM
   TI
   LI
   LO
   TS
CP0374093
(3S,4R)-4-(Benzo[d]isothiazol-3-yloxy)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H16N2O3S
 1
1
EC50 = 16100 nM
   TI
   LI
   LO
   TS
CP0453660
(3S,4R)-4-(5-Chloro-benzooxazol-2-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile
   Show/Hide
C19H16ClN3O3
 1
1
EC50 = 16500 nM
   TI
   LI
   LO
   TS
CP0434936
(3S,4R)-3-hydroxy-2,2-dimethyl-4-[[methyl(phenyl)phosphoryl]amino]-3,4-dihydrochromene-6-carbonitrile
   Show/Hide
C19H21N2O3P
 1
1
EC50 = 18600 nM
   TI
   LI
   LO
   TS
CP0422806
(3S,4R)-4-(5-Chloro-benzo[d]isoxazol-3-ylamino)-3Shydroxy-2,2-dimethyl-chroman-6-yl-phenyl-methanone
   Show/Hide
C25H21ClN2O4
 1
1
EC50 = 20400 nM
   TI
   LI
   LO
   TS
CP0422816
(+/-)-4-cyanophenyl 6-cyano-3-hydroxy-2,2-dimethylchroman-4-ylcarbamate
   Show/Hide
C20H17N3O3
 1
1
EC50 = 21100 nM
   TI
   LI
   LO
   TS
CP0374092
(3S,4R)-6,7-Dichloro-4-(5-chloro-benzo[d]isoxazol-3-ylamino)-2,2-dimethyl-chroman-3-ol
   Show/Hide
C18H15Cl3N2O3
 1
1
EC50 = 24800 nM
   TI
   LI
   LO
   TS
CP0422792
(3S,4R)-3-Hydroxy-2,2-dimethyl-4-(4-methyl-2-phenylimidazol-1-yl)-chroman-6-carbonitrile
   Show/Hide
C22H21N3O2
 1
1
EC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0422807
(3S,4R)-4-(5-Chloro-benzo[d]isoxazol-3-ylamino)-3-hydroxy-2,2-dimethyl-chroman-6-sulfonic acid diethylamide
   Show/Hide
C22H26ClN3O5S
 1
1
EC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0422814
(3S,4R)-6-Chloro-2,2-dimethyl-4-(2-phenyl-imidazol-1-yl)-chroman-3-ol
   Show/Hide
C20H19ClN2O2
 1
1
EC50 > 30000 nM
   TI
   LI
   LO
   TS
Clinical Information about the Protein
Target 1 ( ATP-binding cassette transporter C9 (ABCC9) )
Target Type Successful Target
Disease 4 Target-related Diseases  4
1 Diabetic complication [ICD-11: 5A2Y]
2 Angina pectoris [ICD-11: BA40]
3 Non-insulin dependent diabetes [ICD-11: 5A11]
4 Multiple sclerosis [ICD-11: 8A40]
Approved Drug(s) 4 Approved Drugs  4
1 Glimepiride Approved
Diabetic complication
2 Nicorandil Approved
Angina pectoris
3 Repaglinide Approved
Diabetic complication
4 Tolbutamide Approved
Non-insulin dependent diabetes
Discontinued Drug(s) 2 Discontinued Drugs  2
1 BMS-191095 Discontinued in Phase 1
Angina pectoris
2 CCX915 Discontinued in Phase 1
Multiple sclerosis